Hi Everyone,

According to the Spring 2007 issue of "MSFocus," the quarterly
newsletter of the Multiple Sclerosis Foundation, a much-anticipated
clinical trial of Low Dose Naltrexone (LDN) for MS began in March of
2007 at the University of California's San Francisco MS Research Center.
It is a 17-week, double-blind, crossover study involving 80 patients.

Naltrexone is an FDA-approved medication for drug and alcohol addiction.
Anecdotal reports indicate that, in very low doses, it can be remarkably
effective in treating MS--with minimal side effects and at a price
anyone can afford. Now, at last, the scientific method is being brought
to bear to test those claims.

Because Naltrexone is an inexpensive generic drug, there has been little
commercial interest in sponsoring research. That is to say, the ones to
benefit most from such research are MS sufferers themselves.
Consequently, MS patients who believed they were helped by LDN banded
together to fund the study.

For more information about the clinical trial, contact Elena Kornyeyeva,
M.D., Ph.D., at

elena.kornyeyeva@...

For more information about LDN on the treatment of MS, visit

http://tinyurl.com/2boot2

With best wishes,

Dudley Delany, R.N., M.A., D.C.



http://profiles.yahoo.com/dudley_delany